

**Claims**

1. Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (S)-pantoprazole, and hydrates thereof.
2. Calcium, potassium, zinc and aluminium salts of pantoprazole and (S)-pantoprazole, and hydrates thereof.
3. Calcium (S)-bis[[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
zinc (S)-bis[[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
aluminium (S)-tris[[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
potassium (S)-[[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
calcium bis[[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
zinc bis[[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
aluminium tris[[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole]  
and  
potassium [[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
and the hydrates of these compounds.
4. Lithium (S)-[[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
and  
lithium [[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole],  
and the hydrates of these compounds.
5. A pantoprazole or (S)-pantoprazole salt according to claim 1 or 2 or 3 or 4, or a hydrate thereof, with a particle size distribution of 99 % below 100 µm.
6. Medicament comprising a compound according to any of Claims 1 to 5 together with customary auxiliaries.
7. Medicament comprising a compound according to any of Claims 1 to 5 together with customary auxiliaries, where the single dose comprises from about 10 to about 100 mg of pantoprazole or (S)-pantoprazole, respectively.
8. Use of a compound according to any of Claims 1 to 5 for treating gastrointestinal disorders.

9. Use of a (S)-pantoprazole compound according to any of Claims 1 to 5 for treating gastrointestinal disorders in patients who are slow metabolizers.
10. Use of a compound according to any of Claims 1 to 5 for treating gastrointestinal disorders in patients who have a risk of drug interactions.
11. Use of a compound according to any of Claims 1 to 5 for treating gastrointestinal disorders in patients who need an inhibition of acid secretion for an extended period of time.